- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02093403
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of Selinexor (KPT-330) in combination with decitabine in patients with acute myeloid leukemia (AML).
II. To define the specific toxicities, maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of this combination.
III. To determine the Recommended Phase 2 Dose (RP2D) of this combination.
SECONDARY OBJECTIVES:
I. To determine the overall response rate (ORR). II. To determine the rate and duration of complete remission (CR) +/- hematological recovery of KPT-330 plus decitabine in AML.
III. To conduct pharmacodynamic studies by measuring the effect of this chemotherapy combination on the kinome, micronome and epigenome.
OUTLINE: This is a dose-escalation study of selinexor.
INDUCTION: Patients receive decitabine intravenously (IV) over 1 hour on days 1-10 and Selinexor orally (PO) on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and Selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients with relapsed or refractory AML
- Newly diagnosed elderly AML patients (> 60 years) unfit for intensive chemotherapy with cytarabine and anthracyclines are also eligible to this trial given that no clinically beneficial therapy exists for these patients
- Patients with secondary AML or therapy related disease (t-AML) are eligible; patients who received decitabine or 5-azacytidine as prior treatment for myelodysplastic syndrome (MDS) or AML remain eligible; however, none of these agents is permitted within 6 months of study entry
- If the patient has co-morbid medical illness, life expectancy attributed to this must be greater than 6 months
- Eastern Cooperative Oncology Group (ECOG) performance status < 2
- Total bilirubin < 2.0 mg/dL
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal
- Creatinine < 2.0 mg/d
- Glomerular filtration rate (GFR) > 50 mL/min
- New York Heart Association (NYHA) congestive heart failure (CHF) class II or better
- Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child]bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose
- Ability to understand and willingness to sign the written informed consent document
- Human immunodeficiency virus (HIV) infection without history of acquired immune deficiency syndrome (AIDS) and sufficiently high cluster of differentiation (CD)4 cells (> 400/mm^3) and low HIV viral loads (< 30,000 copies/ml plasma) not requiring anti-HIV therapy are eligible
- Patients must have recovered from the toxicity of prior therapy to less than grade 2
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
- Patients with active central nervous system (CNS) malignancy; asymptomatic small lesions are not considered active; treated lesions may be considered inactive if they are stable for at least 3 months; patients with malignant cells in their cerebrospinal fluid (CSF) without CNS symptoms may be included
- Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed
- Major surgery within 2 weeks before day 1
- Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
- Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus [HBV] surface antigen)
- Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
- History of seizures, movement disorders or cerebrovascular accident within the past 3 years prior to cycle 1 day 1
- Patients with macular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, myocardial infarction within 6 months prior to enrollment, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
- Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Pregnant women or women who are breastfeeding are excluded from this study; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women
- Patients with advanced malignant solid tumors are excluded
- Patients with renal failure (GFR < 50 mL/min) are excluded
- Patients that in the opinion of the investigators are significantly below their ideal body weight
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Treatment (decitabine and selinexor)
INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity. |
Korrelative undersøgelser
Korrelative undersøgelser
Andre navne:
Givet IV
Andre navne:
Givet PO
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
MTD defined as the dose where at most one patient experiences DLT with the next higher dose having at least 2 patients who experience DLT graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
Tidsramme: 31 days
|
31 days
|
|
Incidence of severe (grade 3+) adverse events or toxicities assessed by NCI CTCAE version 4.03
Tidsramme: Up to 3 years
|
The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.
|
Up to 3 years
|
Tolerability of the regimen defined by the number of patients who required dose modifications and/or dose delays
Tidsramme: Up to 3 years
|
Up to 3 years
|
|
Proportion of patients who go off treatment due to adverse reactions
Tidsramme: Up to 3 years
|
Up to 3 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall response rate
Tidsramme: Up to 3 years
|
Responses will be summarized by simple descriptive summary statistics across all dose levels.
Overall response rate will estimated at the MTD and defined as the number of patients who achieve any level of clinical response (e.g.
CR, incomplete blood count recovery, morphologic CR) divided by the total number of evaluable patients (i.e.
any patient who received at least one dose of study treatment).
|
Up to 3 years
|
Complete response rate
Tidsramme: Up to 3 years
|
Responses will be summarized by simple descriptive summary statistics across all dose levels.
Complete response rate will be estimated in those patients treated at the MTD.
|
Up to 3 years
|
Change in expression of XPO1
Tidsramme: Baseline to up to day 31 of course 1
|
Changes in expression of these markers across time will be explored by dose level graphically.
Relationships between baseline expression levels and changes in expression levels with response and certain toxicities will also be explored graphically (e.g.
side-by-side boxplots) and with quantitative summaries.
Confidence intervals will be presented as the primary method of analysis.
Correlations among expression of the genes, micro-ribonucleic acids (miRs), and methylated signatures will be evaluated using scatterplots and the Spearman-rank correlation coefficient.
|
Baseline to up to day 31 of course 1
|
Change in expression of genes associated with XPO1
Tidsramme: Baseline to up to day 31 of course 1
|
Changes in expression of these markers across time will be explored by dose level graphically.
Relationships between baseline expression levels and changes in expression levels with response and certain toxicities will also be explored graphically (e.g.
side-by-side boxplots) and with quantitative summaries.
Confidence intervals will be presented as the primary method of analysis.
Correlations among expression of the genes, miRs, and methylated signatures will be evaluated using scatterplots and the Spearman-rank correlation coefficient.
|
Baseline to up to day 31 of course 1
|
Change in expression of miRs associated with XPO1
Tidsramme: Baseline to up to day 31 of course 1
|
Changes in expression of these markers across time will be explored by dose level graphically.
Relationships between baseline expression levels and changes in expression levels with response and certain toxicities will also be explored graphically (e.g.
side-by-side boxplots) and with quantitative summaries.
Confidence intervals will be presented as the primary method of analysis.
Correlations among expression of the genes, miRs, and methylated signatures will be evaluated using scatterplots and the Spearman-rank correlation coefficient.
|
Baseline to up to day 31 of course 1
|
Change in expression of methylated signatures
Tidsramme: Baseline to up to day 31 of course 1
|
Changes in expression of these markers across time will be explored by dose level graphically.
Relationships between baseline expression levels and changes in expression levels with response and certain toxicities will also be explored graphically (e.g.
side-by-side boxplots) and with quantitative summaries.
Confidence intervals will be presented as the primary method of analysis.
Correlations among expression of the genes, miRs, and methylated signatures will be evaluated using scatterplots and the Spearman-rank correlation coefficient.
|
Baseline to up to day 31 of course 1
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Bhavana Bhatnagar, DO, Ohio State University Comprehensive Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- OSU-13182
- NCI-2014-00559 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut myeloid leukæmi
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RekrutteringMyeloid malignitet | Recidiverende/Refraktær Akut Myeloid LeukæmiKina
-
University of PennsylvaniaAktiv, ikke rekrutterendeAkut myeloid leukæmi, i tilbagefald | Akut myeloid leukæmi, refraktær | Akut myeloid leukæmi, pædiatriskForenede Stater
-
University of WashingtonAfsluttetTilbagevendende akut myeloid leukæmi | Refraktær akut myeloid leukæmi | Myeloid neoplasmaForenede Stater
-
Washington University School of MedicineTrukket tilbageRefraktær akut myeloid leukæmi | Recidiverende akut myeloid leukæmiForenede Stater
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.AfsluttetAkut myeloid leukæmi | Refraktær akut myeloid leukæmi | Recidiverende akut myeloid leukæmiForenede Stater
-
Children's Oncology GroupNational Cancer Institute (NCI)AfsluttetAkut myeloid leukæmi i barndommen/andre myeloid malignitetForenede Stater
-
Xuzhou Medical UniversityRekrutteringAkut myeloid leukæmi, i tilbagefald | Akut myeloid leukæmi refraktærKina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RekrutteringNydiagnosticeret akut myeloid leukæmi (AML)Kina
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RekrutteringAkut myeloid leukæmi, i tilbagefald | Akut myeloid leukæmi refraktærKina
-
Xuzhou Medical UniversityRekrutteringAkut myeloid leukæmi, i tilbagefald | Akut myeloid leukæmi refraktærKina
Kliniske forsøg med laboratoriebiomarkøranalyse
-
Liao Jian AnRekrutteringHoved- og halskræftTaiwan
-
Fondation LenvalTrukket tilbage
-
Progenity, Inc.AfsluttetDowns syndrom | Aneuploidi | DiGeorges syndrom | Turners syndrom | Klinefelters syndrom | Kromosom sletning | Edwards syndrom | Patau syndromForenede Stater
-
IRCCS Eugenio MedeaRekrutteringAutismespektrumforstyrrelse | Tidlig indsatsItalien
-
Oregon Health and Science University4DMedicalTilmelding efter invitationLungesygdomme | KOL | Luftvejssygdom | DyspnøForenede Stater
-
IRCCS Eugenio MedeaRekrutteringCerebral Parese | Erhvervet hjerneskadeItalien
-
Modarres HospitalAfsluttetKomplikationer | Billedstyret biopsi | Nyre GlomerulusIran, Islamisk Republik
-
Healthy.io Ltd.Afsluttet
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadUkendtErhvervsmæssig eksponering | Muskuloskeletal sygdomChile
-
Alcon ResearchAfsluttet